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Cyclic AMP-Mediated Inhibition of Cell Growth Requires the
Small G Protein Rap1
JOHN M. SCHMITT AND PHILIP J. S. STORK*
Vollum Institute, Department of Cell and Developmental Biology, Oregon Health Sciences University,
Portland, Oregon 97201
In many normal and transformed cell types, the intracellular second messenger cyclic AMP (cAMP) blocks
the effects of growth factors and serum on mitogenesis, proliferation, and cell cycle progression. cAMP exerts
these growth-inhibitory effects via inhibition of the mitogen-activated protein (MAP) kinase cascade. Here,
using Hek293 and NIH 3T3 cells, we show that cAMP’s inhibition of the MAP kinase cascade is mediated by
the small G protein Rap1. Activation of Rap1 by cAMP induces the association of Rap1 with Raf-1 and limits
Ras-dependent activation of ERK. In NIH 3T3 cells, Rap1 is required not only for cAMP’s inhibition of ERK
activation but for inhibition of cell proliferation and mitogenesis as well.
Hormones that elevate intracellular cyclic adenosine mono-
phosphate (cAMP) have a wide range of cell-type-specific ef-
fects on cell growth and differentiation (25, 75). In many cell
types, cAMP inhibits the physiological actions of growth fac-
tors (45) and blocks the transformation phenotype in selected
malignant cells (13). For example, in fibroblasts and smooth
muscle cells, cAMP inhibits mitogen-activated protein (MAP)
kinase activation by growth factors (17, 36) and during anchor-
age-independent cell growth (42). These growth-inhibitory ac-
tions are thought to be mediated by G protein pathways that
regulate cAMP (13, 53) and the cAMP-dependent protein
kinase PKA (45).
One of the ways that PKA can oppose the actions of growth
factors is to block growth factor activation of the MAP kinase
cascade. The mechanism of cAMP action has been proposed in
a number of model systems including adipocytes (88), smooth
muscle cells (36), and fibroblasts (17). MAP kinases (or ERKs
[extracellular signal-regulated kinases]) are required for a
broad array of biological processes, including two that are
tightly linked to cellular transformation: mitogenesis (57, 97)
and anchorage-independent cell growth (42). ERKs are re-
quired for the proliferative actions of growth factors in many
cell types (8, 19, 60, 64) through multiple mechanisms (37),
including the regulation of the levels of critical cell cycle pro-
teins (108) including cyclin D1 (50, 58) and p27kip1 (110).
ERKs are activated by growth factors through consecutive
cascades of tyrosine and serine/threonine phosphorylations
(20). The activation of the small G protein Ras serves as a link
between this phosphorylation cascade and the receptors to
which growth factors bind (20, 59). This cascade is initiated by
Ras’s association with (103, 117) and activation of Raf-1, a
ubiquitously expressed protein kinase (2, 68). Raf-1, in turn,
activates MAP kinase kinase (mitogen and extracellular signal-
regulated kinase [MEK]), which then activates ERK (20).
It has previously been established that cAMP’s inhibition of
ERKs maps to a site downstream of Ras and upstream of
Raf-1 (17). cAMP-dependent inhibition of the MAP kinase
cascade requires PKA (36, 88). MEK and ERK are not targets
of PKA, nor is Ras activation by growth factors itself a target
of PKA inhibition (10, 17, 36, 111). In contrast, Raf-1 is both
phosphorylated and inhibited by PKA in vivo. Thus, direct
phosphorylation of Raf-1 by PKA has been proposed to be the
site of action of PKA’s antimitogenic effects (111). Two poten-
tial sites for PKA phosphorylation on Raf-1 have received
significant attention: serine 43 (70, 111) and serine 621 (38,
67). Phosphorylation of serine 43 has been shown to interfere
with Raf-1’s interactions with Ras in vitro (111). Although the
serine 43 site may participate in the inhibitory actions of other
kinases, for example, PKG (92), recent studies have shown that
phosphorylation of this site is not required for PKA’s inhibi-
tion of Raf-1 signaling (89). Serine 621 phosphorylation has
also been proposed to be a site of PKA-dependent inhibition
of Raf-1 activity (38, 67). However, the ability of PKA to
phosphorylate serine 621 in vivo (67) has recently been chal-
lenged (89). Therefore, it is likely that additional mechanisms
of PKA’s inhibition of Raf-1 may play a role in regulating the
action of this kinase.
Another candidate protein that may function to antagonize
Ras-dependent activation of Raf-1 is the small G protein
Rap1. Rap1 was first cloned based on its ability to revert
Ras-dependent transformation of fibroblasts and was initially
named Krev-1 (Kirsten Ras revertant 1) (54). It shares 50%
amino acid sequence homology with Ras, which is greatest in
the effector and the GTPase domains. Two human proteins,
Rap1a and Rap1b, share 97% homology within their amino
acid sequence (79), and both antagonize Ras-induced activa-
tion of mitogenesis and MAP kinase in multiple cell types (12,
18). For example, the constitutively active mutant of Rap1b,
RapV12, has been shown to block Ras-dependent activation of
ERK2 in Rat-1 fibroblasts (18) and to potentiate the transfor-
mation-reverting effect of Rap1 (54). Although Rap1 can be
activated by cAMP (23, 49) and is phosphorylated by PKA (3,
4), the role of Rap1 in cAMP-dependent growth inhibition has
not been examined. The ability of Rap1 to block Ras-depen-
dent signals to ERK has generally been examined in studies
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using transfected Rap1 proteins (18, 44, 54, 61). Indeed, it has
been suggested that endogenous Rap1 does not antagonize
Ras signaling (9, 118, 119). In this study, we examined whether
endogenous Rap1 is required for cAMP’s inhibitory actions on
the MAP kinase cascade and cellular proliferation.
MATERIALS AND METHODS
Materials. Antibodies to Rap1, Raf-1, ERK2 (c-14), and c-Myc (9E10) and
agarose-conjugated antibodies to hemagglutinin (HA) (F-7) and Myc-ERK were
purchased from Santa Cruz Biotechnology Inc (Santa Cruz, Calif.). Antibodies to
HA (12CA5) were purchased from Boehringer Mannheim (Indianapolis, Ind.).
Anti-Ras antibody was purchased from Upstate Biotechnology (Lake Placid,
N.Y.). Phosphorylation-specific AKT antibodies that recognize phosphorylated
AKT (pAKT)/PKB at threonine 308 was purchased from New England Biolabs
(Beverly, Mass.). Phosphorylation-specific ERK antibodies that recognize phos-
phorylated ERK1 and ERK2 (pERK1/2) at residues threonine 183 and tyrosine
185 were purchased from New England Biolabs. Isoproterenol, Flag (M2) anti-
body, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrozolium bromide (MTT)
were purchased from Sigma (St. Louis, Mo.). Forskolin, PD98059, epidermal
growth factor (EGF), and N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinoline-
sulfonamide (H89) were purchased from Calbiochem (Riverside, Calif.). Nickel-
nitrilotriacetic acid-agarose (Ni-NTA-agarose) was purchased from Qiagen Inc.
(Chatsworth, Calif.). [3H]thymidine was purchased from NEN Life Science Prod-
ucts (Boston, Mass.).
Cell culturing conditions and treatments. Hek293 and NIH 3T3 cells were
cultured in Dulbecco modified Eagle medium (DMEM) plus 10% fetal calf
serum at 37°C in 5% CO2. Cells were maintained in serum-free DMEM for 16 h
at 37°C in 5% CO2 prior to treatment with various reagents for coimmunopre-
cipitation assays, Western blotting, and MTT and [3H]thymidine labeling. In all
experiments, cells were treated with isoproterenol (10 mM), EGF (100 ng/ml), or
forskolin (10 mM) for 5 min unless otherwise indicated. Where indicated, cells
were pretreated with isoproterenol or forskolin for 5 min and then stimulated
with EGF for 5 min. H89 (10 mM) and PD98059 (10 mM) were added to cells 20
min prior to treatment.
Western blotting. Cell lysates were prepared as described (87, 105). Cell lysate
protein concentrations were quantified by the Bradford protein assay. For de-
tection of Raf-1, Myc–Raf-1, ERK2, Myc-ERK2, HA, Flag, Ras, Rap1, pAKT,
and pERK1/2, equal protein amounts of cell lysate per treatment condition were
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), blotted onto polyrinylidene difluoride (PVDF) (Millipore Corporation,
Bedford, Mass.) membranes, and probed with the corresponding antibodies
according to the manufacturer’s guidelines.
Plasmids and transfections. Seventy to eighty percent confluent Hek293 or
NIH 3T3 cells were cotransfected with the indicated cDNAs by using a Lipo-
fectamine kit (Gibco BRL) according to the manufacturer’s instructions. The
control vector, pcDNA3 (Invitrogen Corp.), was included in each set of trans-
fections to ensure that each plate received the same amount of DNA. The
control vector pMACS 14.1 (Miltenyi Biotec, Auburn, Calif.) was used for
MACS (magnetic bead cell sorting) selection. Following transfection, cells were
allowed to recover in serum containing medium for 24 h. Cells were then starved
overnight in serum-free DMEM before treatment and lysis.
Nickel affinity chromatography. NIH 3T3 and Hek293 cells were transfected
using Lipofectamine reagent with polyhistidine-tagged Rap1 (His-Rap1 and His-
RapV12) and Ras (His-Ras) as previously described (87). Briefly, cells were lysed
in ice-cold buffer containing 1% NP-40, 10 mM Tris (pH 8.0), 20 mM NaCl, 30
mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, and aprotinin (0.5 mg/ml), and
supernatants were prepared by low-speed centrifugation. Transfected His-tagged
proteins were precipitated from supernatants containing equal amounts of pro-
tein using Ni-NTA-agarose and washed with 20 mM imidazole in lysis buffer and
eluted with 500 mM imidazole and 5 mM EDTA in phosphate-buffered saline.
The eluates containing His-tagged proteins were separated by SDS-PAGE, and
Raf-1 proteins were detected by Western blotting (87, 105). Western blots for
Raf-1 were scanned and analyzed using NIH Image (version 1.57) to quantitate
the amount of Raf-1 protein. Equal amounts of His-Rap1 and His-Ras were
confirmed by Western blotting. Results are presented as means 6 standard
deviations (SD) of multiple experiments.
Affinity assay for Rap1 activation in NIH 3T3 cells. A glutathione S-trans-
ferase (GST) fusion protein of the Rap1 binding domain of RalGDS was ex-
pressed in Escherichia coli following induction by isopropyl-1thio-b-D-galactopy-
ranoside (GST-RalGDS was a gift from J. L. Bos, Utrecht University, Utrecht,
The Netherlands to P. J. S. Stork). NIH 3T3 cells grown as described above were
stimulated at 37°C for the indicated times and immediately lysed in ice-cold lysis
buffer (50 mM Tris-HCl [pH 8.0], 10% glycerol, 1% NP-40, 200 mM NaCl, 2.5
mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 10 mg of
soybean trypsin inhibitor/ml, 10 mM NaF, 0.1 mM aprotinin, 1 mM NaVO4).
Active Rap1 was isolated as described by Franke et al. (31). Briefly, cell lysates
were cleared by centrifugation, and equivalent amounts of supernatants (500 mg)
were incubated with GST-RalGDS Rap1 binding domain precoupled to gluta-
thione beads. Following a 1-h incubation at 4°C, beads were pelleted and rinsed
threes times with ice-cold lysis buffer, and protein was eluted from the beads in
23 Laemmli buffer and applied to an SDS–12% polyacrylamide gel. Proteins
were transferred to a PVDF membrane, blocked in 5% milk for 1 h, and probed
with either Rap1/Krev-1 or Flag antibody overnight at 4°C, followed by a horse-
radish peroxidase-conjugated anti-rabbit secondary antibody (or anti-mouse sec-
ondary for anti-Flag blots). Proteins were detected by enhanced chemilumines-
cence.
Affinity assay for Ras activation in NIH 3T3 cells. NIH 3T3 cells grown as
described above were stimulated at 37°C for the indicated times and immediately
lysed in ice-cold lysis buffer. Activated Ras was isolated according to the man-
ufacturer’s recommended protocol from stimulated lysates, using agarose-cou-
pled GST-Raf1 Ras-binding domain (RBD) provided in an Upstate Biotechnol-
ogy Ras activation assay kit. Proteins were eluted from the beads in 23 Laemmli
buffer and applied to an SDS–12% polyacrylamide gel. Proteins were transferred
to a PVDF membrane, blocked in 5% milk for 1 h, and probed with either Ras
or Flag antibody as indicated overnight at 4°C, followed by a horseradish per-
oxidase-conjugated anti-mouse secondary antibody. Proteins were detected by
enhanced chemiluminescence.
MACS selection of transfected NIH 3T3 cells. NIH 3T3 cells were transfected
with either Flag-Rap1, Rap1GAP1 (see Results), or the pMACS 14.1 control
vector along with the pMACS Kk.II positive selection plasmid as specified by the
manufacturers (Miltenyi Biotec) (46, 96). Cells were also transfected with green
fluorescent protein to monitor both selection and protein expression. Briefly,
cells were transfected using a Lipofectamine kit (Gibco BRL) for 5 h and then
allowed to recover for 24 h. Cells were prepared according to the manufacturer’s
guidelines and incubated with MACSelect Kk microbeads for 20 min with gentle
rocking. Cells were then passed over sterile-prepared MACS separation columns
(type BS) while using a Vario MACS separation magnet. Columns were washed
four times with phosphate-buffered saline supplemented with 0.5% bovine serum
albumin and 5 mM EDTA. Columns were then removed from the Vario MACS
separation magnet, and cells were eluted in DMEM plus 10% fetal calf serum
and recovered on 10-cm-diameter plates. Selected cells were then used for Rap1
assay, the MTT assay, and [3H]thymidine incorporation (described below) at the
indicated times.
MTT assay for cell proliferation in NIH 3T3 cells. NIH 3T3 cells were grown
as described above, serum starved overnight and plated onto 96-well plates. Cells
were then treated and incubated as indicated; 2.5 h prior to lysis, 20 ml of sterile
MTT (2.5 mg/ml) was added, and the cells were allowed to incubate at 37°C. At
the appropriate time, cells were lysed and proteins were solubilized in 50%
(vol/vol) H2O and N,N,-dimethylformamide containing 20% SDS, 0.5% 80%
acetic acid, and 0.4% 1 M HCl. Results were read using a microplate reader and
are presented as the difference between optical densities at 570 and 650 nm.
Thymidine uptake assay for DNA synthesis and proliferation in NIH 3T3 cells.
Serum-starved NIH 3T3 cells were plated at 2 3 104 cells/well on 96-well plates.
Cells were then treated and incubated with serum or EGF in the presence or
absence of forskolin pretreatment. The cells were labeled with [3H]thymidine (1
mCi/well; NEN) 12 h prior to lysis. Cells were then lysed in 50% (vol/vol) H2O
and N,N,-dimethylformamide containing 20% SDS, 0.5% 80% acetic acid, and
0.4% 1 M HCl. Unincorporated counts were removed with an automated har-
vester, and incorporated counts were harvested onto filters. The amount of
[3H]thymidine incorporated was determined with an automated TopCount NXT
version 2.13 scintillation and luminescence counter and software (Packard In-
strument Co., Meriden, Conn.).
RESULTS
Rap1 inhibition of the association of Ras and Raf-1 in
Hek293 cells. EGF stimulates cell growth in a variety of cell
types, via activation of a Ras-dependent signaling cascade to
ERKs. Following stimulation by growth factors, Ras is acti-
vated and subsequently recruits Raf-1 to initiate the MAP
kinase cascade. Association with Ras can be used as an assay
for Raf-1 activation. The association of endogenous Raf-1 with
polyhistidine-tagged Ras (His-Ras) was measured within ly-
sates harvested from transfected cells by nickel affinity chro-
matography, elution, and Western blotting for Raf-1. The
Raf-1 antibody is specific for Raf-1 and does not cross-react
with B-Raf isoforms (87). In Hek293 cells, EGF, but not iso-
proterenol, stimulated the recruitment of endogenous Raf-1 to
Ras. Importantly, EGF’s recruitment of Raf-1 to Ras was in-
hibited by isoproterenol (Fig. 1A), demonstrating that isopro-
terenol’s inhibition of Raf-1 activation occurs at the level of
Ras recruitment of Raf-1, consistent with previous reports in
other cell types (17, 36, 111). In Hek293 cells, isoproterenol
can signal through endogenous b2-adrenergic receptors to ac-
tivate PKA via Gs-coupled signaling pathways (21, 87). In these
cells, isoproterenol can activate Ras, but this action does not
FIG. 1. cAMP’s inhibition of Ras–Raf-1 association by Rap1 in Hek293 cells. (A) Isoproterenol-mediated inhibition of Ras–Raf-1 association
requires PKA. Cells were serum starved overnight and treated with isoproterenol and/or EGF or pretreated with isoproterenol and/or H89 and
then treated with EGF. Top, Western blot of Raf-1 within purified eluates, prepared from equal amounts of His-Ras-transfected Hek293 cell
lysates. Bottom, Western blot of Ras within purified eluates, demonstrating equal amounts of His-Ras proteins within Hek293 cell lysates. (B) Rap1
mediates the ability of isoproterenol to block Ras’s association with endogenous Raf-1. Hek293 cells were transfected with cDNAs encoding
His-Ras and Rap1GAP1 as indicated, serum starved, and stimulated with isoproterenol or EGF or pretreated with isoproterenol and then treated
with EGF. Lysates were then purified using an Ni-NTA-agarose column, and eluates were examined for the presence of either Raf-1 or His-Ras
by Western blotting. The bar graph represents data (6SD) from three pulldown experiments. Bars indicate fold Raf-1 binding over basal. (C)
Isoproterenol induced phosphorylation of AKT does not require PKA. Hek293 cells were stimulated with isoproterenol in the presence or absence
of H89 pretreatment, as indicated. Lysates containing equivalent amounts of protein were probed by Western blotting for pAKT (top) or AKT
(bottom). (D) Rap1 does not regulate AKT activation by Ras and isoproterenol. Hek293 cells were cotransfected with the indicated cDNAs, serum
starved, and stimulated with isoproterenol. Lysates containing equivalent amounts of protein were immunoprecipitated using HA-conjugated
antibody, and purified proteins were probed by Western blotting for either pAKT (top) or HA as a loading control for AKT (middle). Lysates were
also probed by Western blotting for Flag-tagged proteins, Ras, Rap1, and Rap1GAP1 (bottom). Sizes are indicated in kilodaltons. (E) Active Rap1
binds to endogenous Raf-1. Hek293 cells were transfected with cDNAs encoding His-Rap1, HisRapV12, and Rap1GAP1, serum starved, and
stimulated with isoproterenol or EGF. Lysates were then purified using a nickel column, and eluates were examined for the presence of either
Raf-1- or His-Rap-containing proteins (Rap1 or RapV12) by Western blotting. The bar graph represents data (6SD) from three pulldown
experiments. Bars indicate fold Raf-1 binding over basal.
require PKA (87). In contrast, isoproterenol’s inhibition of
Raf-1–Ras association was completely blocked by pretreat-
ment with H89, an inhibitor of the cAMP-dependent protein
kinase PKA (14) (Fig. 1A), suggesting the involvement of PKA
via the intracellular second messenger cAMP.
Previously, it was shown that isoproterenol and cAMP could
activate the small G protein Rap1 (87, 106). Endogenous Rap1
activity can be selectively inhibited by the expression of
Rap1GAP1 (80), a Rap1-specific GTPase-activating protein
that can block Rap1 pathways when expressed ectopically
within cells (6, 85, 113). To test the hypothesis that Rap1 was
involved in the inhibition of Raf-1, we examined Raf-1 recruit-
ment to Ras in cells transfected with Rap1GAP1. EGF stim-
ulated Raf-1 recruitment to Ras, which was unaffected by Rap1
inhibition (Fig. 1B, lanes 5 and 6), suggesting that endogenous
Rap1 does not participate in EGF signaling to Ras and Raf-1
in these cells. However, isoproterenol’s ability to inhibit EGF’s
actions was completely blocked following Rap1 inhibition (Fig.
1B, lanes 7 and 8), demonstrating that endogenous Rap1 me-
diates isoproterenol’s inhibitory effects in these cells. Since
Rap1 is activated by isoproterenol through the actions of
cAMP and PKA (87), these results show that inhibition of
Raf-1 recruitment to Ras by cAMP and PKA required Rap1.
Interestingly, although isoproterenol by itself was incapable of
stimulating the recruitment of Raf-1 to Ras, blocking Rap1
action with Rap1GAP1 revealed isoproterenol’s ability to re-
cruit Raf-1 to Ras (Fig. 1B, lanes 3 and 4). We have previously
shown that despite isoproterenol’s ability to activate Ras in
these cells, isoproterenol does not permit signaling from acti-
vated Ras to Raf-1 and ERK (87). The data presented here
demonstrate that isoproterenol’s activation of Rap1 uncouples
isoproterenol’s activation of Ras signaling from Raf-1 and pro-
vide an explanation for isoproterenol’s inability to activate
Raf-1 while activating Ras.
The mechanism of Rap1 antagonism of Ras-dependent sig-
naling pathways is not well understood. To determine whether
or not Rap1 antagonism of Ras function could be generalizable
to other Ras effectors, we examined another Ras effector in
these cells, phosphoinositide 3-kinase (PI3-K) (26). PI3-K ac-
tivation can be monitored by the phosphorylation of the kinase
AKT (PKB) at threonine 308, through the action of PDK1 (33,
77). Isoproterenol activated AKT in a PKA-independent man-
ner (Fig. 1C). This suggests that the activation of at least one
Ras effector (Raf-1) is blocked by PKA while that of another
(PI3-K) is not. We have shown that isoproterenol’s activation
of Ras in these cells is PKA independent (87), and others have
shown that this requires the action of the bg subunits of the
heterotrimeric G proteins that couple to the b-adrenergic re-
ceptor (55). To determine whether the bg subunits of G pro-
teins are necessary for AKT phosphorylation in response to
isoproterenol, a peptide derived from the carboxyl terminus of
the b-adrenergic receptor kinase 1 (b-ARKct) that sequesters
bg subunits (56) was transfected into cells. b-ARKct has pre-
viously been shown to block bg-dependent signaling down-
stream of G protein-coupled receptors (62). AKT phosphory-
lation was blocked by b-ARKct expression (Fig. 1D), which
suggests that like isoproterenol’s activation of Ras, isoproter-
enol’s activation of AKT is not mediated by Gsa signaling to
PKA but utilizes the bg subunits instead. The Ras dependence
of isoproterenol’s activation of AKT was confirmed by the
ability of RasN17, an interfering mutant of Ras (90), to com-
pletely block the activation of AKT. In contrast, Rap1GAP1
(Fig. 1D) did not block this activation. The inability of Rap1 to
interfere with other Ras-dependent signaling pathways sug-
gests that Rap1 antagonism is selective for Raf-1.
One model for Rap1’s action is that it binds to Raf-1, se-
questering it from Ras (72). Indeed, as isoproterenol blocked
Raf-1’s recruitment to Ras, it increased Raf-1 binding to Rap1
(Fig. 1E, lane 3). Activation of Rap1 was necessary and suffi-
cient for this effect, since Rap1GAP1 blocked this effect (Fig.
1E, lane 4) and RapV12 (a constitutively active mutant of
Rap1 [105]) but not wild-type Rap1 mimicked this effect (Fig.
1E, lanes 2 and 7). EGF did not trigger Raf-1 recruitment to
Rap1 (Fig. 1E), nor did it stimulate GTP loading (data not
shown), confirming that EGF did not activate Rap1 in these
cells.
Rap1 inhibition of the association of Ras and Raf-1 in NIH
3T3 cells. The best-studied consequence of Raf-1’s recruitment
to Ras is the subsequent activation of the MAP kinase kinase
MEK and ERK (1, 7, 15) to stimulate cell proliferation (64,
74). However, the ability of Rap1 to antagonize the activation
of MEK and ERK and cell growth is cell type specific (5, 29,
105, 112, 115) and depends on the specific Raf isoform(s)
expressed in a given cell (72). For example, both cAMP (105)
and Rap1 can activate B-Raf (71), a potent activator of MEK,
and both cAMP and Rap1 are activators of ERK signaling in
B-Raf-expressing cells (105). Hek293 cells express the 95-kDa
isoform of B-Raf, which confers regulation by PKA (63, 83). In
these cells, both isoproterenol and cAMP-PKA can activate
ERK through Rap1 (87). To examine cAMP’s inhibition of
ERK in a B-Raf-negative cell type, we chose NIH 3T3 cells.
These cells do not express B-Raf (105), and they have been a
model system for the study of cAMP on ERKs and cell growth
(13, 111).
Forskolin is a potent activator of adenylyl cyclase and rapidly
increases cAMP levels and PKA activity in all cell types. In
NIH 3T3 cells, forskolin rapidly activated Rap1 (Fig. 2A and
B), as measured by a GST-RalGDS assay (31). In contrast,
EGF did not activate Rap1 (Fig. 2B and C), nor did it stimulate
the association between Rap1 and Raf-1 (Fig. 2D). As an
independent test for the requirement of PKA in forskolin’s
actions, we transfected the cDNA encoding PKI, a specific
inhibitor of PKA (22). Briefly, cells were transfected with Flag-
Rap1, Rap1GAP1, PKI, cPKA (catalytic subunit of PKA), or
vector DNA along with cDNA encoding the truncated mouse
major histocompatibility class I molecule H-2Kk, and trans-
fected cells were separated using anti-H-2Kk coupled to MAC-
Select Kk microbeads (Miltenyi Biotec) as described in Mate-
rials and Methods. Importantly, either PKI or Rap1GAP1
blocked the actions of both transfected and endogenous Rap1
(Fig. 2C). These results demonstrate that cAMP’s activation of
endogenous Rap1 in these cells required PKA and was blocked
by Rap1GAP1. Binding of GTP-Ras to the Raf-1 RBD in vitro
can be used to monitor EGF’s stimulation of Ras GTP loading
(Fig. 2E). While EGF potently activated Ras, forskolin did not,
nor did forskolin alter EGF’s activation of Ras (Fig. 2E). This
suggests that forskolin inhibits Ras-dependent activation of
Raf-1, without affecting Ras activation (GTP loading) itself.
Moreover, Rap1GAP1 did not block Ras activation (Fig. 2F),
suggesting that its actions on Rap1 (Fig. 2C and D) were
selective (86).
Forskolin inhibited Ras recruitment of endogenous Raf-1 in
NIH 3T3 cells, as shown for Hek293 cells (Fig. 3A and C). The
action of forskolin was blocked by pretreatment with H89 or
transfection of PKI and was mimicked by RapV12 (Fig. 3A).
Examining endogenous Ras association with Myc-tagged Raf-1
showed the same results; forskolin blocked EGF’s action, and
FIG. 2. Rap1 activation by cAMP in NIH 3T3 cells. (A) cAMP stimulation activates Rap1. NIH 3T3 cells were serum starved and stimulated
with forskolin for the indicated times. Lysates containing equivalent amounts of protein (500 mg) were incubated with GST-RalGDS and probed
by Western blotting for active Rap1. NIH 3T3 lysate (3T3 lysate; 10mg) was used as a control to indicate the position of Rap1 (top). Total lysates
were probed for Rap1 as a control for protein loading (bottom). (B) EGF does not activate Rap1 in NIH 3T3 cells. Serum-starved NIH 3T3 cells
were treated with EGF for the indicated times or with forskolin (5 min). Lysates containing equivalent amounts of protein were incubated with
GST-RalGDS and probed by Western blotting for active Rap1. NIH 3T3 lysate (3T3 lysate; 50 mg) was used as a control to indicate the position
of Rap1 (top). Total lysates were probed for Rap1 to control for protein loading (bottom). (C) Rap1GAP1 and PKI block forskolin’s activation
of both transfected and endogenous Rap1. NIH 3T3 cells were transfected with Rap1GAP1, PKI, cPKA, or vector along with pMACS Kk.II, and
transfected cells were positively selected as described in Materials and Methods. Transfected cells were treated with forskolin or EGF or left
untreated, and Rap1 assays were performed with GST-RalGDS. Western blotting with anti-Rap1 antibodies identified activation of endogenous
Rap1 (bottom) and transfected Flag-Rap1 (top). (D) EGF does not induce the association of Rap1 with endogenous Raf-1. NIH 3T3 cells were
transfected with His-Rap1 and Rap1GAP1, serum starved, and stimulated with EGF or forskolin as a positive control. Lysates containing
equivalent amounts of protein were then purified using a nickel column, and eluates were examined for the presence of Raf-1 (upper panel) and
His-Rap1 (lower panel) by Western blotting using Raf-1 and Rap1 antisera, respectively. (E) EGF, but not cAMP, activates Ras in NIH 3T3 cells.
Cells were serum starved and stimulated with forskolin or EGF for the indicated times or were pretreated with forskolin and then stimulated with
EGF. Lysates containing equivalent amounts of protein were incubated with GST-Raf1 RBD and probed by Western blotting for active Ras (top).
Total lysates were probed for Ras to control for protein loading (bottom). NIH 3T3 lysate (3T3 lysate; 50 mg) was used as a control to indicate
the position of Ras. (F) Rap1GAP1 does not interfere with Ras activation. NIH 3T3 cells were cotransfected with Flag-Ras and Rap1GAP1 or
Flag-Ras alone. Transfected cells were left untreated or treated with forskolin or EGF as indicated, and Ras assays were performed with GST-Raf1
RBD. Western blotting with Flag antibody was performed to identify activated Flag-Ras.
this was blocked by H89 (Fig. 3B). The requirement of Rap1
activation for forskolin’s inhibition of Ras–Raf-1 association is
shown in Fig. 3C. Inactivating endogenous Rap1 by expressing
Rap1GAP1 in these cells prevented forskolin’s inhibitory ac-
tions (Fig. 3C, lanes 7 and 8). The activation of Rap1 by
forskolin not only uncoupled Raf-1 from Ras activation but
also triggered the association of Rap1 with endogenous Raf-1
(Fig. 3D and F). This association required PKA, since it was
blocked by either H89 or PKI (Fig. 3D). In addition, forskolin
stimulated the association of endogenous Rap1 with Myc-
tagged Raf-1 in the presence or absence of EGF, and this was
blocked by H89 (Fig. 3E). Moreover, it required activated
Rap1, as it was blocked by the ectopic expression of
Rap1GAP1 (Fig. 3F) and could be mimicked by RapV12 (Fig.
FIG. 3. Requirement of Rap1 for cAMP’s ability to block Ras and Raf-1 association in NIH 3T3 cells. (A) cAMP blocked the association of
Ras with endogenous Raf-1 via PKA. NIH 3T3 cells were transfected with cDNAs encoding His-Ras, Flag-RapV12, or PKI, serum starved, and
stimulated with EGF in the presence or absence of forskolin after pretreatment with H89. Lysates were then purified using a nickel column, and
eluates were examined for the presence of Raf-1 (top) or His-Ras (bottom) by Western blotting. (B) cAMP blocked the association of Raf-1 with
endogenous Ras via PKA. NIH 3T3 cells were transfected with cDNA encoding Myc–Raf-1, serum starved, and stimulated with EGF in the
presence or absence of forskolin after pretreatment with H89 as indicated. Lysates were then immunoprecipitated with Myc antibody and probed
for Ras (top) or Myc–Raf-1 (bottom) by Western blotting. (C) cAMP blocked Ras–Raf-1 association via Rap1. NIH 3T3 cells were transfected
with cDNA encoding His-Ras or Rap1GAP1, serum starved, and stimulated with forskolin or EGF or pretreated with forskolin and then treated
with EGF. Lysates were then purified using a nickel column, and eluates were examined for the presence of either Raf-1 or His-Ras by Western
blotting. The bar graph represents data (6SD) from three pulldown experiments. Bars indicate fold Raf-1 binding over basal (fold over basal). (D)
cAMP blocked the association of Rap1 with endogenous Raf-1 via PKA. cAMP triggered the association between Rap1 and Raf-1 via PKA. NIH
3T3 cells were transfected with cDNAs encoding His-Rap1, HisRapV12, or PKI, serum starved, and stimulated with forskolin in the presence or
absence of H89. Lysates were then purified using a nickel column, and eluates were examined for the presence of Raf-1 (top) or His-Rap-
containing proteins (bottom) by Western blotting. (E) cAMP blocked the association of Raf-1 with endogenous Rap1 via PKA. NIH 3T3 cells were
transfected with cDNA encoding Myc–Raf-1, serum starved, and stimulated with EGF in the presence or absence of forskolin after pretreated with
H89 as indicated. Lysates were then immunoprecipitated with Myc antibody and probed for Rap1 (top) or Myc–Raf-1 (bottom) by Western
blotting. (F) Active Rap1 binds to Raf-1. NIH 3T3 cells were transfected with cDNAs encoding His-Rap1, HisRapV12, and Rap1GAP1 as
indicated, serum starved, and stimulated with forskolin or pretreated with forskolin prior to stimulation by EGF. Lysates were then purified using
a nickel column, and eluates were examined for the presence of either Raf-1 or His-Rap-containing proteins (Rap1 or RapV12) by Western
blotting. The bar graph represents data (6SD) from three pulldown experiments. Bars indicate fold Raf-1 binding over basal (fold over basal).
3D and F). Thus, in both Hek293 and NIH 3T3 cells, cAMP’s
inhibition of Raf-1 binding to Ras required Rap1 and PKA.
Rap1 and cAMP’s inhibition of ERKs and cell proliferation
in NIH 3T3 cells. ERK activation can be measured by Western
blotting using phosphospecific antibodies that recognize the
activating phosphates within the ERK activation loop (116).
Using this assay, forskolin inhibited activation of endogenous
ERK by EGF in NIH 3T3 cells (Fig. 4A), confirming previous
FIG. 4. cAMP blockade of EGF’s activation of ERKs via Rap1. (A) cAMP’s inhibition of ERK phosphorylation by EGF requires PKA. NIH
3T3 cells were serum starved and treated with forskolin, H89, or EGF or pretreated with forskolin and/or H89 and then treated with EGF, as
indicated. Lysates containing equivalent amounts of protein were probed for phosphorylation of endogenous ERK (pERK1/2) as well as total ERK
(ERK2) to control for loading. (B) Extended time course of forskolin’s inhibition of EGF’s activation of ERK. Cells were treated with EGF,
forskolin (Fork.), or H89 for the times indicated and analyzed as for panel A. (C) Rap1 antagonizes Ras’s activation of ERKs. NIH 3T3 cells were
transfected with cDNAs encoding Myc-ERK2, Flag-RasV12, and Flag-RapV12, serum starved, and treated with EGF as indicated. Lysates
containing equivalent amounts of protein were immunoprecipitated (IP) with Myc-conjugated antibody and immunoblotted (IB) by Western
blotting for pERK (p-MycERK2) or Myc (MycERK2) to control for protein loading. The levels of both transfected proteins Flag-RasV12 and
Flag-RapV12 are also shown, following Flag immunoprecipitation (IP) and Ras, Rap1, or Flag immunoblotting (IB), as indicated (lower panels).
(D) Rap1 mediates cAMP’s ability to inhibit EGF stimulation of ERK phosphorylation. NIH 3T3 cells were transfected with cDNAs encoding
Myc-ERK2, RapV12, and Rap1GAP1, serum starved, and treated with forskolin or EGF or pretreated with forskolin and then treated with EGF,
as indicated. Lysates containing equivalent amounts of protein were immunoprecipitated with Myc-conjugated antibody and probed by Western
blotting for pERK (p-MycERK2) or Myc (MycERK2) to control for protein loading. (E) Forskolin activates Rap1 and inhibits ERKs in a
dose-dependent manner. NIH 3T3 cells were serum starved, pretreated with the indicated concentrations of forskolin and then treated with EGF
as indicated, or untreated (Un). Lysates containing equivalent amounts of protein were either probed for phosphorylation of endogenous ERK
(pERK1/2) (top) or total ERK (ERK2) to control for protein loading (middle) or used for Rap1 activation assay (bottom). (F) H89 blocks
forskolin’s activation of Rap1 and its inhibition of ERKs in a dose-dependent fashion. NIH 3T3 cells were serum starved, pretreated with the
indicated concentration of H89, treated with forskolin, and then stimulated with EGF as indicated. Lysates containing equivalent amounts of
protein were either probed for phosphorylation of endogenous ERK (pERK1/2) (top) or total ERK (ERK2) to control for protein loading
(middle) or used for Rap1 activation assay (bottom).
results (111), and this action of forskolin, but not EGF, was
blocked by H89, demonstrating the specificity of H89 and con-
firming a role for PKA in forskolin’s inhibition of ERKs. An
extended time course of Forskolin’s action is shown in Fig. 4B.
Activated Rap1 (RapV12) did not stimulate ERKs in NIH 3T3
cells; rather, it blocked the activation of ERKs by activated Ras
(RasV12) (Fig. 4C), suggesting that overexpression of Rap1
was sufficient to antagonize Ras-dependent signals in NIH 3T3
cells, as in other cell types (18). The proteins appeared to be
expressed to equivalent levels, as judged by Flag Western blot-
ting (lower panels). To determine whether endogenous Rap1
was necessary for Forskolin’s inhibition of ERK activation, we
examined ERK activation in the presence and absence of
Rap1GAP1. The expression of Rap1GAP1 blocked the action
of forskolin to inhibit EGF-dependent activation of ERK (Fig.
4D). These data demonstrate that cAMP’s activation of Rap1
mediated cAMP’s block of Ras-dependent signaling to Raf-1,
MEK, and ERK in NIH 3T3 cells. To compare the relative
effectiveness of forskolin to activate Rap1 and inhibit ERK, we
examined the dose dependency of these actions of forskolin.
For both actions, forskolin showed similar 50% effective con-
centrations (roughly 1.0 mM) (Fig. 4E). H89 blocked both
actions of forskolin with a 50% inhibitory concentration of
roughly 0.4 mM (Fig. 4F), a dose that is selective for PKA (14).
At the highest dose used, H89 had no effect on the PKA-
independent activation of Rap1 by thrombin (data not shown)
(32, 87). These results and those for assays using PKI (Fig. 3)
demonstrate that in NIH 3T3 cells, PKA is required for Rap1’s
activation by cAMP. To determine whether Rap1 mediates
cAMP’s inhibition of cell growth in NIH 3T3 cells, we first
confirmed that forskolin blocked EGF’s proliferative actions in
these cells. Both EGF and serum (10%) stimulated cell pro-
liferation, as measured 96 h later. Similar results were seen at
24 and 48 h (data not shown). All of these proliferative re-
sponses were blocked by inhibiting MEK with PD98059 and by
pretreatment with forskolin (Fig. 5A). Forskolin’s actions were
blocked by H89, demonstrating that PKA was required. Fors-
kolin did not induce apoptotic changes in these cells during the
course of the experiment (data not shown). Taken together,
the data confirm that EGF stimulates proliferation via ERK
and that cAMP-PKA inhibition of ERK activation blocks
EGF’s proliferative effects (Fig. 5A). To test whether Rap1
activation was required for forskolin’s antiproliferative actions,
we examined proliferation in cells transfected with Rap1GAP1
and positively selected as described above. In all conditions
where forskolin inhibited the proliferative effects of EGF or
serum, these effects were completely blocked by the expression
of Rap1GAP1 (Fig. 5B). Similar results were seen examining
mitogenesis, as measured by [3H]thymidine uptake (Fig. 6).
The ability of EGF or serum to stimulate [3H]thymidine up-
take was blocked by PD98059, demonstrating the requirement
of MEK for these effects. Forskolin also blocked the mitogenic
actions of both EGF and serum. This inhibition required PKA,
as forskolin’s antimitogenic actions were blocked by H89 (Fig.
6A). H89 had no effect on the proliferation of untreated cells.
As for cell proliferation, in all conditions where forskolin in-
hibited the mitogenic effects of EGF or serum, these effects
were completely blocked by the expression of Rap1GAP1 (Fig.
6B). These data demonstrate that the activation of endogenous
Rap1 is required to mediate cAMP’s inhibition of cell growth
and proliferation.
DISCUSSION
Most studies examining cAMP’s inhibition of ERK have
focused on cAMP’s regulation of either Ras (10) or Raf-1
FIG. 5. Requirement of Rap1 for cAMP’s ability to block EGF-induced cell proliferation. (A) Forskolin blocked cell proliferation induced by
either serum or EGF. NIH 3T3 cells were serum starved, plated into 96-well plates, and placed into either 0.5% serum (low serum), EGF, or 10%
serum (serum) plus forskolin (Forsk.), PD98059 (PD), or H89, as indicated. Forskolin was applied 5 min prior to either EGF or serum addition,
as indicated. MTT assay buffer was added to the cells 2.5 h prior to the indicated time of lysis, the results were read using a microplate reader and
are presented as the difference between optical densities (OD) at 570 and 650 nm [OD(570–650)]. The bar graph represents data (6SD) from five
independent experiments. (B) Rap1GAP1 reverses cAMP’s inhibitory effects on NIH 3T3 cell proliferation. NIH 3T3 cells were transfected with
cDNAs encoding pMACS 14.1 or Rap1GAP1 and pMACS Kk.II and then positively selected as described in Materials and Methods. Selected cells
were serum starved, plated into 96-well plates, and placed into either 0.5% serum (low serum), EGF (100 ng/ml), or 10% serum (serum) plus
forskolin, PD98059, or H89, as indicated. MTT assay buffer was added to the cells 2.5 h prior to the indicated time of lysis; the results were read
using a microplate reader and are presented as for panel A.
signaling (17, 38, 67, 89, 111). This is largely because of the
critical role of Ras signaling in proliferation (30) and in onco-
genesis and metastasis (107). Ras is thought to stimulate cell
cycle progression by multiple mechanisms (34). One of the
earliest consequences of Ras action on cell proliferation is the
stimulation of G1/S transition (34, 94, 95). Although Raf-1/
ERK is the best-studied stimulator of cellular proliferation in
NIH 3T3 cells (19, 74) as well as other fibroblast cells (91),
oncogenic Ras activation of non-Raf-1/ERK pathways is suf-
ficient to cause malignant transformation (51). Specific Ras
effectors distinct from Raf-1 have been implicated in Ras’s
actions on cell growth and proliferation in selected cell types,
including Rho (51, 82), Rac-1 (16, 47, 69, 73), PI3-K (27, 93,
98), and RalGDS (24, 40, 66, 109). Although the stimulation of
cell growth clearly involves multiple Ras effectors, Raf-1/ERK
appears to mediate the initial events in this transition, by stim-
ulating the expression of cyclin D1 (34) and possibly by de-
creasing the levels of the cell cycle inhibitor p27 (48, 50, 110).
Therefore, cAMP’s inhibition of Ras/ERK signaling may in-
hibit cell growth in a variety of cell types where cell cycle
proteins are tightly regulated by ERK. In NIH 3T3 cells,
growth factor stimulation of cell growth requires Ras and
MEK (19, 64), suggesting that Raf-1 is a critical effector of Ras’
proliferative actions in these cells.
The ability of cAMP to block Ras-dependent signals was
examined in both Hek293 and NIH 3T3 cells. In Hek293 cells,
both Raf-1 and PI3-K are downstream of Ras (Fig. 1). Al-
though cAMP inhibited Ras recruitment of Raf-1, it did not
block the Ras-dependent activation of PI3-K, ruling out the
general inhibition of Ras function as a mechanism for cAMP’s
actions. Indeed, recent reports suggest that under certain cir-
cumstances, cAMP can actually stimulate Ras (11, 78, 100).
The studies presented here using Hek293 cells demonstrate
that cAMP can selectively block Raf-1-dependent processes
without affecting Ras activation and function.
A number of potential models by which cAMP can inhibit
Raf-1 signaling have been proposed, some of which postulate
a direct action of PKA on Raf-1 itself (38, 67, 111). Most
studies have examined the phosphorylation of Raf-1 at serine
43 within the amino terminus (111). In one study, recombinant
Raf-1 phosphorylated by PKA at this site in vitro bound less
well to GTP-loaded Ras than did unphosphorylated Raf-1,
although this difference was not greater than 50%, and was
absent when higher concentrations of unphosphorylated and
phosphorylated Raf-1 proteins were examined (52). Indeed,
contrary conclusions have been drawn from studies performed
in vivo. Studies in both Hek293 and NIH 3T3 cells have dem-
onstrated that phosphorylation at serine 43 in Raf-1 is dispens-
able for cAMP’s inhibitory effects (89), and the role of serine
43 phosphorylation in Raf-1 regulation remains unknown.
Support for additional mechanisms of PKA’s ability to reg-
ulate Raf-1 comes from examination of the Raf isoform B-Raf.
It has been previously shown that the association of B-Raf with
Ras, like that of Raf-1, is also blocked following cAMP stim-
ulation (76, 87, 89, 102). B-Raf lacks a PKA consensus site at
the residue analogous to serine 43. Therefore, the ability of
cAMP to block B-Raf–Ras association suggests that the direct
phosphorylation of Raf cannot fully account for PKA’s inhibi-
tion of the Raf family of kinases (89). We propose that the
same protein or proteins upstream of both Raf-1 and B-Raf
may mediate these effects. Interestingly, as for Ras–Raf-1, this
block of Ras–B-Raf association by cAMP is also inhibited by
the expression of Rap1GAP1 (data not shown). However, this
action does not block ERK activation, since ERKs are acti-
vated by Rap1 in B-Raf-expressing cells (87, 105, 112), via the
activation of B-Raf by Rap1 itself (71).
FIG. 6. Requirement of Rap1 for cAMP’s ability to block EGF-induced DNA synthesis. (A) Forskolin blocked DNA synthesis induced by
either serum or EGF. NIH 3T3 cells were serum starved, plated into 96-well plates, and placed into either 0.5% serum (low serum), EGF, or 10%
serum (serum) plus forskolin (Forsk.), PD98059 (PD), or H89. Forskolin was applied 5 min prior to either EGF or serum addition. [3H]thymidine
uptake assays were performed as described in Materials and Methods, and the data are presented as means 6SD (n 5 5). (B) Rap1GAP1 reverses
cAMP’s inhibitory effects on NIH 3T3 cell mitogenesis. NIH 3T3 cells were transfected with cDNAs encoding pMACS 14.1 or Rap1GAP1 and
pMACS Kk.II and then positively selected as described in Materials and Methods. Selected cells were serum starved, plated into 96-well plates,
and placed into either 0.5% serum (low serum), EGF, or 10% serum (serum) plus forskolin, PD98059, or H89. Forskolin was applied 5 min prior
to either EGF or serum addition, and [3H]thymidine uptake was measured as described in Materials and Methods. The data are presented as for
panel A.
Our data suggest that PKA’s actions do not require direct
phosphorylation of Raf-1. It is possible that cAMP’s activation
of Rap1 prevents Ras from associating with Raf-1 by direct
binding as suggested by other studies (72, 117), although ad-
ditional studies may be necessary to establish this model in
vivo. For example, biochemical experiments have shown that
Ras has a higher affinity for Raf-1 than does Rap1 (41), sug-
gesting that sequestration of Raf-1 by Rap1 in vivo may occur
only when the level of activated Rap1 protein exceeds that of
Ras. Given that the transfection of Rap1 and Ras result in
similar levels of expression (Fig. 4C), it is possible that the
ability of Rap1 to block Ras signals to ERKs in vivo may
proceed by another mechanism. We propose that Rap1 acti-
vation by cAMP may block the activation of Raf-1 by Ras,
thereby limiting signals downstream of Raf-1, including MEK
and ERK, resulting in the inhibition of cell proliferation and
mitogenesis. These studies implicating cAMP-PKA activation
of Rap1 are distinct from those studies in other cell types
identifying a PKA-independent activation of Rap1 (28, 101,
104), presumably via cAMP-guanine nucleotide exchange fac-
tors (23, 49).
Studies examining PKA actions on Rap1 have focused on
the direct phosphorylation of Rap1 by PKA. PKA phosphor-
ylates both Rap1a and Rap1b at a site within the carboxyl
terminus (serine 179 in Rap1b). Rap1 is a target of phospho-
ryation following cAMP elevation in vivo (84, 105) and in vitro
(3). PKA phosphorylation of Rap1 at this site has been pro-
posed to enhance Rap1 activation (39), inhibit Rap1 coupling
(43), or have only modest effects (3).
Although the regulation of Rap1 by direct phosphorylation
remains controversial, direct phosphorylation of Rap1 has
been proposed to influence its association with specific effec-
tors (43). Hu et al. showed that PKA decreases the association
of Rap1 and Raf-1 (43). In contrast, using transfected Rap1b,
we show that in both Hek293 cells and NIH 3T3 cells PKA
increases the association of Rap1b with Raf-1 (Fig. 1E and 3D
to F) via the activation of Rap1 itself. In that study, the de-
crease in affinity of Rap1 and Raf-1 was due to the PKA-
dependent phosphorylation of serine 180 in Rap1a, which de-
creases Rap1’s affinity for the cysteine-rich domain of Raf-1.
Both Rap1a and Rap1b are targets of PKA phosphorylation in
vivo. Therefore, it is unlikely that the differences in our finding
with Hu et al. relate to differences between the two Rap1
isoforms. These differences may be due to distinct biochemical
properties of truncated Raf-1 fragments used in those studies
or may reflect cell-type-specific effects. In any case, the precise
mechanism of Rap1 stimulation by PKA remains unknown,
and the role of PKA’s phosphorylation of Rap1 in this process
is not well understood. Importantly, targets of PKA that lie
upstream of Rap1 itself have not been ruled out. These targets
will be subjects of future research.
Because Hek293 cells express B-Raf, examination of the
inhibitory role of Rap1 in cAMP inhibition of ERKs is com-
plicated by Rap1’s simultaneous activation of B-Raf and ERKs
in these cells (87, 112). To enable us to examine the role of
Rap1 in cAMP-mediated inhibition of ERKs, we used NIH3T3
cells. These cells express little or no B-Raf (105) and have been
previously used as a model for cAMP-dependent inhibition of
cell growth. One study showed that expression of constitutive
activation of Gsa suppresses Ras-dependent proliferation and
cellular transformation (13). In another study, PKA activation
during anchorage-independent growth of these cells blocked
ERK activation by growth factors, in part, via PKA’s inhibition
of PAK (42). However, inhibition of PAK could not entirely
account for PKA’s inhibitory actions, and additional targets of
PKA were proposed (42). Interestingly, in studies examining
signaling pathways during anchorage-dependent cell growth
and cell adhesion, Rap1 regulation has been reported (81, 85,
99).
As with other members of the MAP kinase family (35), the
kinetics of ERK activation are critical for determining the
consequence of ERK signaling (65, 110, 114), and modest
reductions in ERK activation may be physiologically signifi-
cant. For example, in CCL39 fibroblast cells, PKA inhibition of
ERK is transient (65). We show in NIH 3T3 cells that sus-
tained activation of cAMP blocks ERK activation completely
and for an extended period of time, suggesting that the extent
of cAMP’s inhibition may be cell type specific.
In NIH 3T3 cells, EGF stimulated ERK phosphorylation,
cell proliferation, and mitogenesis. EGF’s stimulation of cell
proliferation and mitogenesis was blocked by PD98059, con-
sistent with the requirement for MEK and ERK for growth
factor-induced cell growth in these cells (19, 64, 74). cAMP
blocked all three aspects of EGF’s actions—stimulation of
ERKs, cell proliferation, and mitogenesis—suggesting that
cAMP’s inhibition of mitogenesis was dictated, in part, by its
inhibition of ERKs. We show here that Rap1 is required for
cAMP’s inhibitory actions of Raf-1, ERK activation, cellular
proliferation, and mitogenesis. The ability of cAMP and PKA
to block ERK activation by growth factors inhibits two central
aspects of malignant transformation, cellular proliferation and
anchorage-independent cell growth (42). We show here that
Rap1 is a critical component of PKA’s inhibition of ERK-
dependent mitogenesis.
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